EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group

Wagner, Anna Dorothea ; Grabsch, Heike I ; Mauer, Murielle ; Marreaud, Sandrine ; Caballero, Carmela ; Thuss-Patience, Peter ; Mueller, Lothar ; Elme, Annelie ; Moehler, Markus Hermann ; Martens, Uwe ; Kang, Yoon-Koo ; Rha, Sun Young ; Cats, Annemieke ; Tokunaga, Masanori ; Lordick, Florian

BMC cancer, 2019-05, Vol.19 (1), p.494-494, Article 494 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível